Targeted disruption of leucine-rich repeat kinase 1 but not leucine-rich repeat kinase 2 in mice causes severe osteopetrosis

Journal of Bone and Mineral Research

Volumn 28, Issue 9, 2013, Pages 1962-1974

  Xing, Weirong ^a,b   Liu, Jeff ^c   Cheng, Shaohong ^a   Vogel, Peter ^c,d   Mohan, Subburaman ^a,b   Brommage, Robert ^c  

^a Jerry L Pettis Memorial VA Medical Center   (United States)

^b LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LEXICON PHARMACEUTICALS INC   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

BONE DENSITY; BONE RESORPTION; c SRC; CSK; KNOCKOUT; OSTEOCLAST; PIT FORMATION

Indexed keywords

ALKALINE PHOSPHATASE; CARBOXY TERMINAL TELOPEPTIDE; LEUCINE RICH REPEAT KINASE 1; LEUCINE RICH REPEAT KINASE 2; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN SERINE THREONINE KINASE; RECOMBINANT COLONY STIMULATING FACTOR 1; TYROSINE; UNCLASSIFIED DRUG;

ALBERS SCHOENBERG DISEASE; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MASS; BONE MINERALIZATION; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE OVEREXPRESSION; IMMUNOPRECIPITATION; KNOCKOUT MOUSE; MALE; MOUSE; MULTINUCLEAR CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE SRC; OSTEOCLAST; OSTEOLYSIS; OVARIECTOMY; PHENOTYPE; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TRABECULAR BONE;

BONE DENSITY; BONE RESORPTION; C-SRC; CSK; KNOCKOUT; OSTEOCLAST; PIT FORMATION;

ACID PHOSPHATASE; ALKALINE PHOSPHATASE; ANIMALS; BONE AND BONES; BONE DENSITY; BONE RESORPTION; FEMALE; GENE TARGETING; ISOENZYMES; MICE; MICE, KNOCKOUT; MUTANT PROTEINS; OSTEOCLASTS; OSTEOGENESIS; OSTEOPETROSIS; OVARIECTOMY; PEPTIDE FRAGMENTS; PHENOTYPE; PHOSPHORYLATION; PROCOLLAGEN; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS PP60(C-SRC); SRC-FAMILY KINASES; X-RAY MICROTOMOGRAPHY;

EID: 84882701498     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1935     Document Type: Article

References (54)

1. Segovia-Silvestre T, Neutzsky-Wulff AV, Sorensen MG, Christiansen C, Bollerslev J, Karsdal MA, Henriksen K., Advances in osteoclast biology resulting from the study of osteopetrotic mutations. Hum Genet. 2009; 124 (6): 561-77.
2. Feng X, McDonald JM., Disorders of bone remodeling. Annu Rev Pathol. 2011; 6: 121-45.
3. Redlich K, Smolen JS., Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov. 2012; 11 (3): 234-50.
4. Glaser DL, Kaplan FS., Osteoporosis. Definition and clinical presentation. Spine (Phila Pa 1976). 1997 Dec 15; 22 (24 Suppl): 12S- 16S.
5. Deal C., Bone loss in rheumatoid arthritis: systemic, periarticular, and focal. Curr Rheumatol Rep. 2012; 14 (3): 231-7.
6. Pepelassi E, Nicopoulou-Karayianni K, Archontopoulou A, Mitsea A, Kavadella A, Tsiklakis K, Vrotsos I, Devlin H, Horner K., The relationship between osteoporosis and periodontitis in women aged 45-70. years. Oral Dis. 2012; 18 (4): 353-9.
7. Suleiman Martos Y, Avilés Pérez MD, Escobar Jimenez F, Muñoz Torres ME., [Multiple myeloma as a cause of rapidly progressive osteoporosis]. Endocrinol Nutr. 2012 Jun-Jul; 59 (6): 398-400. Spanish.
8. [No authors listed.] Denosumab. Limited efficacy in fracture prevention, too many adverse effects. Prescrire Int. 2011; 20 (117): 145-8.
9. Kidd LJ, Cowling NR, Wu AC, Kelly WL, Forwood MR., Bisphosphonate treatment delays stress fracture remodeling in the rat ulna. J Orthop Res. 2011; 29 (12): 1827-33.
10. Nase JB, Suzuki JB., Osteonecrosis of the jaw and oral bisphosphonate treatment. J Am Dent Assoc. 2006; 137 (8): 1115-9; quiz 1169-70.
11. Taylor KH, Middlefell LS, Mizen KD., Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg. 2010; 48 (3): 221-3.
12. Bosgraaf L, Van Haastert PJ., Roc, a Ras/GTPase domain in complex proteins. Biochim Biophys Acta. 2003; 1643 (1-3): 5-10.
13. Mosavi LK, Cammett TJ, Desrosiers DC, Peng ZY., The ankyrin repeat as molecular architecture for protein recognition. Protein Sci. 2004; 13 (6): 1435-48.
14. Kobe B, Kajava AV., The leucine-rich repeat as a protein recognition motif. Curr Opin Struct Biol. 2001; 11 (6): 725-32.
15. Marin I., The Parkinson disease gene LRRK2: evolutionary and structural insights. Mol Biol Evol. 2006; 23 (12): 2423-33.
16. Biskup S, Moore DJ, Rea A, Lorenz-Deperieux B, Coombes CE, Dawson VL, Dawson TM, West AB., Dynamic and redundant regulation of LRRK2 and LRRK1 expression. BMC Neurosci. 2007; 8: 102.
17. Takahashi Y, Miyata M, Zheng P, Imazato T, Horwitz A, Smith JD., Identification of cAMP analogue inducible genes in RAW264 macrophages. Biochim Biophys Acta. 2000; 1492 (2-3): 385-394.
18. Korr D, Toschi L, Donner P, Pohlenz HD, Kreft B, Weiss B., LRRK1 protein kinase activity is stimulated upon binding of GTP to its Roc domain. Cell Signal. 2006; 18 (6): 910-20.
19. Titz B, Low T, Komisopoulou E, Chen SS, Rubbi L, Graeber TG., The proximal signaling network of the BCR-ABL1 oncogene shows a modular organization. Oncogene. 2010; 29 (44): 5895-10.
20. Ishikawa K, Nara A, Matsumoto K, Hanafusa H., EGFR-dependent phosphorylation of leucine-rich repeat kinase LRRK1 is important for proper endosomal trafficking of EGFR. Mol Biol Cell. 2012; 23 (7): 1294-306.
21. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T., Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004; 44 (4): 601-7.
22. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA., Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci. 2006; 9 (10): 1231-3.
23. Herzig MC, Kolly C, Persohn E, Theil D, Schweizer T, Hafner T, Stemmelen C, Troxler TJ, Schmid P, Danner S, Schnell CR, Mueller M, Kinzel B, Grevot A, Bolognani F, Stirn M, Kuhn RR, Kaupmann K, van der Putten PH, Rovelli G, Shimshek DR., LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet. 2011; 20 (21): 4209-23.
24. Zambrowicz BP, Abuin A, Ramirez-Solis R, Richter LJ, Piggott J, BeltrandelRio H, Buxton EC, Edwards J, Finch RA, Friddle CJ, Gupta A, Hansen G, Hu Y, Huang W, Jaing C, Key BW Jr, Kipp P, Kohlhauff B, Ma ZQ, Markesich D, Payne R, Potter DG, Qian N, Shaw J, Schrick J, Shi ZZ, Sparks MJ, Van Sligtenhorst I, Vogel P, Walke W, Xu N, Zhu Q, Person C, Sands AT., Wnk1 kinase deficiency lowers blood pressure in mice: a gene-trap screen to identify potential targets for therapeutic intervention. Proc Natl Acad Sci U S A. 2003; 100 (24): 14109-14.
25. Donoviel DB, Freed DD, Vogel H, Potter DG, Hawkins E, Barrish JP, Mathur BN, Turner CA, Geske R, Montgomery CA, Starbuck M, Brandt M, Gupta A, Ramirez-Solis R, Zambrowicz BP, Powell DR., Proteinuria and perinatal lethality in mice lacking NEPH1, a novel protein with homology to NEPHRIN. Mol Cell Biol. 2001; 21 (14): 4829-36.
26. Brommage R, Desai U, Revelli JP, Donoviel DB, Fontenot GK, Dacosta CM, Smith DD, Kirkpatrick LL, Coker KJ, Donoviel MS, Eberhart DE, Holt KH, Kelly MR, Paradee WJ, Philips AV, Platt KA, Suwanichkul A, Hansen GM, Sands AT, Zambrowicz BP, Powell DR., High-throughput screening of mouse knockout lines identifies true lean and obese phenotypes. Obesity (Silver Spring). 2008; 16 (10): 2362-7.
27. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R., Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010; 25 (7): 1468-86.
28. Xing W, Pourteymoor S, Mohan S., Ascorbic acid regulates osterix expression in osteoblasts by activation of prolyl hydroxylase and ubiquitination-mediated proteosomal degradation pathway. Physiol Genomics. 2011; 43 (12): 749-57.
29. Xing W, Kim J, Wergedal J, Chen ST, Mohan S., Ephrin B1 regulates bone marrow stromal cell differentiation and bone formation by influencing TAZ transactivation via complex formation with NHERF1. Mol Cell Biol. 2010; 30 (3): 711-21.
30. Zheng HF, Tobias JH, Duncan E, Evans DM, Eriksson J, Paternoster L, Yerges-Armstrong LM, Lehtimaki T, Bergstrom U, Kahonen M, Leo PJ, Raitakari O, Laaksonen M, Nicholson GC, Viikari J, Ladouceur M, Lyytikainen LP, Medina-Gomez C, Rivadeneira F, Prince RL, Sievanen H, Leslie WD, Mellstrom D, Eisman JA, Moverare-Skrtic S, Goltzman D, Hanley DA, Jones G, St Pourcain B, Xiao Y, Timpson NJ, Smith GD, Reid IR, Ring SM, Sambrook PN, Karlsson M, Dennison EM, Kemp JP, Danoy P, Sayers A, Wilson SG, Nethander M, McCloskey E, Vandenput L, Eastell R, Liu J, Spector T, Mitchell BD, Streeten EA, Brommage R, Pettersson-Kymmer U, Brown MA, Ohlsson C, Richards JB, Lorentzon M., WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk. PLoS Genet. 2012; 8 (7): e1002745.
31. Beamer WG, Donahue LR, Rosen CJ, Baylink DJ., Genetic variability in adult bone density among inbred strains of mice. Bone. 1996; 18 (5): 397-403.
32. Qin X, Wergedal JE, Rehage M, Tran K, Newton J, Lam P, Baylink DJ, Mohan S., Pregnancy-associated plasma protein-A increases osteoblast proliferation in vitro and bone formation in vivo. Endocrinology 2006; 147 (12): 5653-61.
33. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR., Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2 (6): 595-610.
34. Leeming DJ, Larsen DV, Zhang C, Hi Y, Veidal SS, Nielsen RH, Henriksen K, Zheng Q, Barkholt V, Riis BJ, Byrjalsen I, Qvist P, Karsdal MA., Enzyme-linked immunosorbent serum assays (ELISAs) for rat and human N-terminal pro-peptide of collagen type I (PINP)-assessment of corresponding epitopes. Clin Biochem. 2010; 43 (15): 1249-56.
35. Xing W, Baylink D, Kesavan C, Mohan S., HSV-1 amplicon-mediated transfer of 128-kb BMP-2 genomic locus stimulates osteoblast differentiation in vitro. Biochem Biophys Res Commun. 2004; 319 (3): 781-6.
36. Cheng S, Zhao SL, Nelson B, Kesavan C, Qin X, Wergedal J, Mohan S, Xing W., Targeted disruption of ephrin b1 in cells of myeloid lineage increases osteoclast differentiation and bone resorption in mice. PLoS One. 2012; 7 (3): e32887.
37. Xing W, Singgih A, Kapoor A, Alarcon CM, Baylink DJ, Mohan S., Nuclear factor-E2-related factor-1 mediates ascorbic acid induction of osterix expression via interaction with antioxidant-responsive element in bone cells. J Biol Chem. 2007; 282 (30): 22052-61.
38. Lowe C, Yoneda T, Boyce BF, Chen H, Mundy GR, Soriano P., Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. Proc Natl Acad Sci U S A. 1993; 90 (10): 4485-9.
39. Nakayama H, Takakuda K, Matsumoto HN, Miyata A, Baba O, Tabata MJ, Ushiki T, Oda T, McKee MD, Takano Y., Effects of altered bone remodeling and retention of cement lines on bone quality in osteopetrotic aged c-Src-deficient mice. Calcif Tissue Int. 2010; 86 (2): 172-83.
40. Miyazaki T, Tanaka S, Sanjay A, Baron R., The role of c-Src kinase in the regulation of osteoclast function. Mod Rheumatol. 2006; 16 (2): 68-74.
41. Okada M., Regulation of the SRC family kinases by Csk. Int J Biol Sci. 2012; 8 (10): 1385-97.
42. Joukov V, Vihinen M, Vainikka S, Sowadski JM, Alitalo K, Bergman M., Identification of csk tyrosine phosphorylation sites and a tyrosine residue important for kinase domain structure. Biochem J. 1997; 322 (Pt 3): 927-35.
43. Lee S, Lin X, Nam NH, Parang K, Sun G., Determination of the substrate-docking site of protein tyrosine kinase C-terminal Src kinase. Proc Natl Acad Sci U S A 2003; 100 (25): 14707-12.
44. Kawabuchi M, Satomi Y, Takao T, Shimonishi Y, Nada S, Nagai K, Tarakhovsky A, Okada M., Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases. Nature 2000; 404 (6781): 999-1003.
45. Matsuoka H, Nada S, Okada M., Mechanism of Csk-mediated down-regulation of Src family tyrosine kinases in epidermal growth factor signaling. J Biol Chem. 2004; 279 (7): 5975-83.
46. Imamoto A, Soriano P., Disruption of the csk gene, encoding a negative regulator of Src family tyrosine kinases, leads to neural tube defects and embryonic lethality in mice. Cell. 1993; 73 (6): 1117-24.
47. Miyazaki T, Takayanagi H, Isshiki M, Takahashi T, Okada M, Fukui Y, Oda H, Nakamura K, Hirai H, Kurokawa T, Tanaka S., In vitro and in vivo suppression of osteoclast function by adenovirus vector-induced csk gene. J Bone Miner Res. 2000; 15 (1): 41-51.
48. Sun G, Ke S, Budde RJ., Csk phosphorylation and inactivation in vitro by the cAMP-dependent protein kinase. Arch Biochem Biophys. 1997; 343 (2): 194-200.
49. Vang T, Torgersen KM, Sundvold V, Saxena M, Levy FO, Skalhegg BS, Hansson V, Mustelin T, Tasken K., Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor. J Exp Med. 2001; 193 (4): 497-507.
50. Baker MA, Hetherington L, Aitken RJ., Identification of SRC as a key PKA-stimulated tyrosine kinase involved in the capacitation-associated hyperactivation of murine spermatozoa. J Cell Sci. 2006; 119 (Pt 15): 3182-92.
51. Chen L, Wang Y, Wells D, Toh D, Harold H, Zhou J, DiGiammarino E, Meehan EJ., Structure of the SH3 domain of human osteoclast-stimulating factor at atomic resolution. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2006; 62 (Pt 9): 844-8.
52. Reddy S, Devlin R, Menaa C, Nishimura R, Choi SJ, Dallas M, Yoneda T, Roodman GD., Isolation and characterization of a cDNA clone encoding a novel peptide (OSF) that enhances osteoclast formation and bone resorption. J Cell Physiol. 1998; 177 (4): 636-45.
53. Langton PF, Colombani J, Aerne BL, Tapon N., Drosophila ASPP regulates C-terminal Src kinase activity. Dev Cell. 2007; 13 (6): 773-82.
54. Izawa T, Zou W, Chappel JC, Ashley JW, Feng X, Teitelbaum SL., c-Src links a RANK/alphavbeta3 integrin complex to the osteoclast cytoskeleton. Mol Cell Biol. 2012; 32 (14): 2943-53.